Last week, Tesla released its electric vehicle delivery results for the third quarter of 2025, and the numbers surprised investors. The automaker managed to increase deliveries by 7% year-over-year to 497,099 vehicles, surpassing Wall Street expectations by more than 49,000 units. However, despite this, Tesla’s stock price fell by 5.11%* after the announcement, ultimately suggesting that the market is looking beyond the headline figure.

InvestingFox, a registered trademark of CAPITAL MARKETS, o.c.p., a.s., warns against unfair practices associated with the misuse of its brand. InvestingFox distances itself from any activities or projects of similar-sounding brands.

At the beginning of the week, shares of pharmaceutical giant AstraZeneca rose by 1.5%* on the London Stock Exchange. The reason? It was a reaction to the planned transfer of trading from Nasdaq via American Depositary Receipts directly to the New York Stock Exchange (NYSE). In response, investors in Europe began to wonder: “What would such a move mean for my portfolio?”

The tech world was rocked by the news of a groundbreaking alliance between Nvidia, currently the most valuable company in the world, and Intel, the historically iconic chip manufacturer. From an investment perspective, this is a collaboration that has the potential to significantly strengthen the intrinsic value of both companies by expanding their product portfolios into highly promising areas.[1]